Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Neurology · Paroxysmal Movement Disorders

Matching Treatment to the Cause: Standard of Care Options

At a Glance

Treatment for a child’s paroxysmal movement disorder should match the genetic cause: a supervised ketogenic diet may help Glut1 deficiency, while targeted medicines may help specific movement or coordination attacks. Ongoing monitoring is essential.

Treating paroxysmal movement disorders is not a “one size fits all” approach. Because these conditions are caused by different biological “glitches”—some involving energy and others involving electrical signaling—the treatment must be matched to your child’s specific genetic cause [1][2].

Energy-Based Treatment: The Ketogenic Diet (SLC2A1/Glut1)

For children with SLC2A1 (Glut1 deficiency), the standard of care is Ketogenic Dietary Therapy (KDT) [1]. This is a medical diet, high in fat and low in carbohydrates, that must be supervised by a specialized medical team [3].

  • How it Works: The diet forces the body to burn fat for fuel, creating ketone bodies. These ketones act as an “alternative fuel” that the brain can use easily, bypassing the broken glucose gateway [4].
  • What to Expect: While seizures often improve within days or weeks, movement symptoms—like balance issues (ataxia) or involuntary movements—may take months to show significant improvement [5].
  • Success Rates: Small observational studies show that many patients (up to 82% in some cohorts) see an improvement in movement symptoms, though response rates and timing vary [5]. In some cases, the movements resolve completely [6].
  • Long-Term Monitoring: Because the diet is a major change for the body, your team requires scheduled clinical and laboratory follow-up to monitor your child’s height, weight, bone density, electrolytes, kidney function, and cholesterol levels, as well as providing a sick-day and hypoglycemia plan [7][8]. They will also watch for side effects like kidney stones, which can often be prevented with supplements [9][3].

Signaling-Based Treatments: Medications

When the issue is electrical “static” or “leaky” channels, doctors use specific medications to stabilize the brain’s signals. Never start, stop, or change an antiseizure drug without the treating clinician’s explicit instruction.

  • Carbamazepine and Oxcarbazepine (PRRT2): These are the preferred treatments for Paroxysmal Kinesigenic Dyskinesia (PKD). They work by blocking “sodium channels” to prevent sudden bursts of electrical activity [10]. These medications are often highly effective even at very low doses, and attacks may stop within just a few days of starting treatment [11][12]. However, they require discussion of serious risks, including severe rash, liver toxicity, and low blood sodium (hyponatremia).
  • Acetazolamide (CACNA1A/KCNA1): This is frequently used for Episodic Ataxia. It helps stabilize the electrical environment in the coordination center of the brain [13]. In clinical trials, it has been shown to reduce the number of attacks by about half [13]. It carries risks of metabolic/electrolyte problems and kidney stones [13].
  • Benzodiazepines (PNKD): For families with Paroxysmal Non-Kinesigenic Dyskinesia, doctors may use medications like clonazepam to help manage attacks when they occur [14]. Clonazepam has limited evidence and carries sedation, dependence, and respiratory-depression risks; it should not be framed as a routine attack rescue medication without a specialist-directed plan.

The Role of Trigger Avoidance

Regardless of the medication or diet used, managing “lifestyle triggers” is a cornerstone of care. This is especially true for PNKD, where symptoms are often brought on by external factors [15].

  • Stress and Fatigue: Ensuring your child gets consistent sleep and has tools to manage emotional stress can reduce attack frequency [16].
  • Dietary Triggers: For some children, avoiding specific triggers like caffeine is a simple but effective strategy [17].
  • Fasting: For children with energy-related issues not on a ketogenic diet, managing meal timing can help prevent the “dips” in energy that lead to an attack [18]. Note: Do not use unsupervised carbohydrate snacks if your child is on a prescribed ketogenic diet, as it can dangerously alter ketosis.

Some children have coexisting epilepsy or need symptomatic treatment. Never stop antiseizure medication abruptly [1][19]. Therapies such as physical, occupational, and speech therapy can also help address persistent spasticity and ataxia.

Common questions in this guide

How is treatment selected for a child's paroxysmal movement disorder?
Treatment is matched to the gene involved and the type of episodes. A supervised ketogenic diet is standard care for SLC2A1-related Glut1 deficiency, while carbamazepine or oxcarbazepine is commonly used for PRRT2-related paroxysmal kinesigenic dyskinesia. Acetazolamide is often used for episodic ataxia linked to CACNA1A or KCNA1, and clonazepam may be considered for some PNKD cases.
How does ketogenic dietary therapy help children with Glut1 deficiency?
A ketogenic diet is high in fat and low in carbohydrates, so the body makes ketones that the brain can use as an alternative fuel when glucose transport is impaired. Seizures may improve within days or weeks, but balance problems and involuntary movements can take months to improve. The diet must be prescribed and monitored by a specialized medical team.
How quickly can medicines reduce movement attacks?
Carbamazepine and oxcarbazepine can stop PRRT2-related PKD attacks within a few days in some children, often at low doses. Acetazolamide may reduce episodic ataxia attacks, while clonazepam may help some PNKD symptoms but has limited evidence. The treating clinician should decide how long to trial a medicine and whether to adjust it.
What serious side effects should I watch for with these treatments?
Carbamazepine and oxcarbazepine can cause severe rash, liver injury, or low blood sodium. Acetazolamide can cause electrolyte or metabolic problems and kidney stones, while clonazepam can cause sedation, dependence, and slowed breathing. Ask the treating clinician which symptoms require urgent medical attention for your child.
What monitoring is needed during a ketogenic diet?
The medical team may monitor your child's growth, weight, bone density, electrolytes, kidney function, cholesterol, and ketone levels. Families should also have a sick-day and low-blood-sugar plan, and clinicians may recommend supplements to help prevent kidney stones. Do not add unsupervised carbohydrate snacks because they can disrupt prescribed ketosis.
Can sleep, diet, or trigger avoidance reduce paroxysmal attacks?
Consistent sleep, stress-management strategies, and avoiding a child's known triggers may reduce attacks; caffeine is a trigger for some children. Regular meal timing may help children with energy-related problems who are not following a ketogenic diet. A child on a prescribed ketogenic diet should not receive unsupervised carbohydrate snacks, because they can dangerously change ketosis.
Do children need therapy in addition to diet or medication?
Physical, occupational, and speech therapy may help persistent spasticity, balance problems, and other functional difficulties. These therapies support daily function but do not replace treatment directed at the underlying genetic cause. The care team can tailor rehabilitation to your child's needs.

Get notified when new evidence is published on Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Diagnosis and treatment recommendations for glucose transporter 1 deficiency syndrome.

    Zhang MJ, Wu , Yu LF, et al.

    World journal of pediatrics : WJP 2025; (21(2)):149-158 doi:10.1007/s12519-024-00864-5.

    PMID: 39745620
  2. 2

    Paroxysmal Dyskinesias in Paediatric Age: A Systematic Review.

    Pisanò G, Gnazzo M, Sigona G, et al.

    Journal of clinical medicine 2025; (14(17)) doi:10.3390/jcm14175925.

    PMID: 40943684
  3. 3

    Ketogenic diet therapy for the treatment of pediatric epilepsy.

    Haridas B, Testino A, Kossoff EH

    Epileptic disorders : international epilepsy journal with videotape 2025; (27(2)):144-155 doi:10.1002/epd2.20320.

    PMID: 39665749
  4. 4

    Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group.

    Klepper J, Akman C, Armeno M, et al.

    Epilepsia open 2020; (5(3)):354-365 doi:10.1002/epi4.12414.

    PMID: 32913944
  5. 5

    Glucose transporter type 1 deficiency syndrome and the ketogenic diet.

    Schwantje M, Verhagen LM, van Hasselt PM, Fuchs SA

    Journal of inherited metabolic disease 2020; (43(2)):216-222 doi:10.1002/jimd.12175.

    PMID: 31605543
  6. 6

    Efficacy and safety evaluation of ketogenic diet therapy in patients with glucose transporter type 1 deficiency syndrome.

    Wang M, Liu L, Shang L, et al.

    Frontiers in nutrition 2026; (13()):1920521 doi:10.3389/fnut.2026.1920521.

    PMID: 42824025
  7. 7

    Long-term follow-up of nutritional status in children with GLUT1 Deficiency Syndrome treated with classic ketogenic diet: a 5-year prospective study.

    De Amicis R, Leone A, Pellizzari M, et al.

    Frontiers in nutrition 2023; (10()):1148960 doi:10.3389/fnut.2023.1148960.

    PMID: 37293674
  8. 8

    Analysis of dietary fats intake and lipid profile in Chilean patients with glucose transport type 1 deficiency syndrome: similarities and differences with the reviewed literature.

    Salazar MF, Leal-Witt MJ, Parga V, et al.

    Frontiers in nutrition 2024; (11()):1390799 doi:10.3389/fnut.2024.1390799.

    PMID: 38818131
  9. 9

    Classic Ketogenic Diet and Modified Atkins Diet in SLC2A1 Positive and Negative Patients with Suspected GLUT1 Deficiency Syndrome: A Single Center Analysis of 18 Cases.

    Ruiz Herrero J, Cañedo Villarroya E, González Gutiérrez-Solana L, et al.

    Nutrients 2021; (13(3)) doi:10.3390/nu13030840.

    PMID: 33806661
  10. 10

    Clinical features of patients with paroxysmal kinesigenic dyskinesia, mutation screening of PRRT2 and the effects of morning draughts of oxcarbazepine.

    Pan G, Zhang L, Zhou S

    BMC pediatrics 2019; (19(1)):439 doi:10.1186/s12887-019-1798-7.

    PMID: 31722684
  11. 11

    Characteristics of infantile convulsions and choreoathetosis syndrome caused by PRRT2 mutation.

    Deng Y, Xu J, Yao C, et al.

    Pediatric investigation 2022; (6(1)):11-15 doi:10.1002/ped4.12308.

    PMID: 35382417
  12. 12

    Paroxysmal kinesigenic dyskinesia: Clinical and genetic analyses of 110 patients.

    Huang XJ, Wang T, Wang JL, et al.

    Neurology 2015; (85(18)):1546-53 doi:10.1212/WNL.0000000000002079.

    PMID: 26446061
  13. 13

    Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-Controlled Trial.

    Muth C, Teufel J, Schöls L, et al.

    Neurology. Clinical practice 2021; (11(4)):e438-e446 doi:10.1212/CPJ.0000000000001017.

    PMID: 34484942
  14. 14

    Paroxysmal movement disorders - practical update on diagnosis and management.

    De Gusmao CM, Silveira-Moriyama L

    Expert review of neurotherapeutics 2019; (19(9)):807-822 doi:10.1080/14737175.2019.1648211.

    PMID: 31353980
  15. 15

    Treatment of paroxysmal dyskinesias in children.

    Mink JW

    Current treatment options in neurology 2015; (17(6)):350 doi:10.1007/s11940-015-0350-9.

    PMID: 25864940
  16. 16

    Protein mutated in paroxysmal dyskinesia interacts with the active zone protein RIM and suppresses synaptic vesicle exocytosis.

    Shen Y, Ge WP, Li Y, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2015; (112(10)):2935-41 doi:10.1073/pnas.1501364112.

    PMID: 25730884
  17. 17

    Sertraline treatment for paroxysmal nonkinesigenic dyskinesia comorbid with anxiety and depression.

    Hara M, Matsuishi T, Takahashi S, Yamashita Y

    eNeurologicalSci 2024; (36()):100520 doi:10.1016/j.ensci.2024.100520.

    PMID: 39211314
  18. 18

    Movement disorders in GLUT1 deficiency syndrome: a systematic review of the literature.

    Bercini Z, Gessani A, Rossi J, et al.

    Journal of neurology 2026; (273(8)).

    PMID: 42406126
  19. 19

    [Clinical characteristics and ketogenic diet therapy of glucose transporter type 1 deficiency syndrome in children: a multicenter clinical study].

    Yu LF, Zhang YQ, Duan J, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(11)):881-886 doi:10.3760/cma.j.cn112140-20200822-00819.

    PMID: 33120458

This page is for informational purposes only and does not constitute medical advice. Your child's treating clinician and specialized diet team should guide medication, ketogenic diet, and monitoring decisions.

Guide contents Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity
Research & Literature
04 Decoding the Data 06 The Long-Term Path